All > Paid Studies Nebraska > Maryland
Verified

KIN-2787 for Melanoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Melanoma+2 MoreKIN-2787 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, KIN-2787, for safety and effectiveness in adults with solid tumors that have BRAF or NRAS mutations.

Eligible Conditions
  • Melanoma
  • Solid Tumors, Adult
  • Non-small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
PF-07284890
1
SRF388
1
DZ-002

Study Objectives

11 Primary · 12 Secondary · Reporting Duration: Initiation of study drug until disease progression (up to approximately 36 months)

Month 18
Incidence of dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and incidence of clinically significant changes in vital signs, physical examinations, ECGs, and clinical laboratory tests.
Part A1 Dose escalation monotherapy
Part A2 Dose Escalation: KIN-2787 + Binimetinib Combination
Month 4
Area under the plasma concentration-time curve (AUC).
Plasma
Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to AUC.
Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to Cmax.
Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to tmax.
Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to AUC.
Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to Cmax.
Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to tmax.
Part B Dose Expansion: characterization of PK properties of KIN-2787 including, but not limited to AUC.
Part B Dose Expansion: characterization of PK properties of KIN-2787 including, but not limited to Cmax.
Part B Dose Expansion: characterization of PK properties of KIN-2787 including, but not limited to tmax.
Time to achieve Cmax (Tmax)
Month 36
In Part B (Dose Expansion) - disease control rate (DCR).
In Part B (Dose Expansion) - duration of overall response (DOR).
In Part B (Dose Expansion) - duration of stable disease.
In Part B (Dose Expansion) - objective response rate (ORR) using RECIST v1.1.
In Part B (dose expansion) - disease control rate (DCR).
In Part B (dose expansion) - duration of overall response (DOR).
In Part B (dose expansion) - duration of stable disease.
In Part B (dose expansion) - objective response rate (ORR) using RECIST v1.1.

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
PF-07284890
1
SRF388
1
DZ-002

Trial Design

5 Treatment Groups

Dose Escalation
1 of 5
Dose Expansion
1 of 5
Dose Expansion (Part B)
1 of 5
Dose Escalation Combination therapy (Part A2)
1 of 5
Dose Escalation Monotherapy (Part A1)
1 of 5

Experimental Treatment

155 Total Participants · 5 Treatment Groups

Primary Treatment: KIN-2787 · No Placebo Group · Phase 1

Dose Escalation
Drug
Experimental Group · 1 Intervention: KIN-2787 · Intervention Types: Drug
Dose Expansion
Drug
Experimental Group · 1 Intervention: KIN-2787 · Intervention Types: Drug
Dose Expansion (Part B)
Drug
Experimental Group · 1 Intervention: KIN-2787 · Intervention Types: Drug
Dose Escalation Combination therapy (Part A2)
Drug
Experimental Group · 1 Intervention: KIN-2787 and binimetinib · Intervention Types: Drug
Dose Escalation Monotherapy (Part A1)
Drug
Experimental Group · 1 Intervention: KIN-2787 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: initiation of study drug until disease progression (up to approximately 36 months)

Who is running the clinical trial?

Kinnate BiopharmaLead Sponsor
1 Previous Clinical Trials
120 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
California60.0%
Florida40.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria80.0%
Met criteria20.0%
What site did they apply to?
Stanford Cancer Center50.0%
Providence Medical Foundation (St. Joseph's)50.0%
How many prior treatments have patients received?
0100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top